EyePoint Inc
EYPT
Company Profile
Business description
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Contact
480 Pleasant Street
Suite C-400
WatertownMA02472
USAT: +1 833 393-7646
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
144
Stocks News & Analysis
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,125.30 | 32.40 | -0.35% |
| CAC 40 | 8,103.84 | 290.48 | -3.46% |
| DAX 40 | 23,753.02 | 884.98 | -3.59% |
| Dow JONES (US) | 48,561.44 | 343.34 | -0.70% |
| FTSE 100 | 10,452.50 | 327.61 | -3.04% |
| HKSE | 25,265.05 | 503.03 | -1.95% |
| NASDAQ | 22,516.69 | 232.17 | -1.02% |
| Nikkei 225 | 54,090.11 | 2,188.94 | -3.89% |
| NZX 50 Index | 13,500.14 | 156.51 | -1.15% |
| S&P 500 | 6,827.79 | 53.83 | -0.78% |
| S&P/ASX 200 | 8,906.10 | 30.90 | -0.35% |
| SSE Composite Index | 4,086.29 | 36.38 | -0.88% |